BGI Diagnostics achieves Chinese approval for non-invasive fetal trisomy test

The CFDA had approved the registration of the company’s BGISEQ-1000 and BGISEQ-100 sequencers, and its prenatal genetic testing kits for the NIFTY test in June 2014.

CFDA’s approval makes the NIFTY test the only certified non-invasive prenatal test currently available in China.

BGI Diagnostics’ non-invasive maternal blood test detects the risk for certain fetal chromosomal (aneuploidy) disorders, such as Down syndrome, from as early as week ten of pregnancy.

The NIFTY test is also provided across Europe.

Sign up for our weekly news round-up!

Give your business an edge with our leading industry insights.

Sign up